DasPAQT: Treating Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Dasatinib - PCR-Monitoring, Adherence, Quality of Life, Therapy Satisfaction (OMC 2014-I; BMS CA180-565)

Tesch H, Pelz H, Janssen J, Hansen R, Fietz T, Anhuf J, Häberle L, Belleville E, Steinmetz T, Azeh I, Schardt C (2016)

Publication Type: Conference contribution

Publication year: 2016

Journal

Oncology Research and Treatment Karger Publishers

Book Volume: 39

Pages Range: 118-118

Involved external institutions

Centrum für Hämatologie und Onkologie Bethanien DE Germany (DE) ClinSol GmbH & Co.KG DE Germany (DE) MVZ Onkologie GmbH DE Germany (DE) CORRECTIV – Recherchen für die Gesellschaft gemeinnützige GmbH DE Germany (DE) Onko.LogiẊ GmbH & Co.KG. DE Germany (DE) Ambulantes Therapiezentrum für Hämatologie und Onkologie DE Germany (DE)

How to cite

APA:

Tesch, H., Pelz, H., Janssen, J., Hansen, R., Fietz, T., Anhuf, J.,... Schardt, C. (2016). DasPAQT: Treating Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Dasatinib - PCR-Monitoring, Adherence, Quality of Life, Therapy Satisfaction (OMC 2014-I; BMS CA180-565). (pp. 118-118).

MLA:

Tesch, H., et al. "DasPAQT: Treating Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Dasatinib - PCR-Monitoring, Adherence, Quality of Life, Therapy Satisfaction (OMC 2014-I; BMS CA180-565)." 2016. 118-118.

BibTeX: Download